MMPSense™ 750 FAST is Presented at AACR 100th Annual Meeting

Lt. Governor Murray and other Massachusetts Dignitaries on Hand to Celebrate Rapid Growth of Acceleron Product Pipeline and Plans to Further Increase Workforce

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active cellular therapies to treat vascular and other serious diseases, today announced that it has received Orphan Drug Designation for Vascugel®, a novel allogeneic cell therapy product that may restore natural repair and regeneration pathways in the vasculature, from the U.S. Food and Drug Administration (FDA).

RX-10045 Promotes Corneal Epithelial Repair in Model System

Topical Administration of Resolvin Effective in Model of Wet AMD

The Helicos System Produces Better Scientific Results with Less Sequencing Required

LEXINGTON, Mass -- Concert Pharmaceuticals, Inc. announced today that its first patents have been granted by the U.S. Patent and Trademark Office. These patents relate to specific compounds derived from Concert’s deuterium chemistry platform. U.S. Patents 7,514,068 and 7,528,131 specifically claim deuterium analogs of rimonabant and mosapride, respectively. In addition to these patents, Concert has over 100 pending U.S. patent applications and corresponding applications worldwide.

SAB Members Elected to NAS and IOM; Honored with Awards from AACR and NFCR

Achieves First Instrument Revenue and Significant Milestones

CAMBRIDGE, Mass., May 14, 2009 -- Helicos BioSciences Corporation (NASDAQ: HLCS) announced today its financial results for the quarter ended March 31, 2009.

Confirms P&G’s Commitment to Sustainable Innovation

Accelerates LS9’s Entry into the Consumer Product Chemicals Market

Industry Leaders Bring Deep Oncology and Company Building Experience